Enzian Pharmaceutics' Expandable Fibrous Dosage Form Triples Bioavailability of Sparingly-Soluble Drugs
核心洞察
Enzian Pharmaceutics (搜索) has developed an innovative expandable fibrous dosage form that resides in the stomach for six hours and delivers three times greater bioavailability than conventional capsules for sparingly-soluble drugs.
The technology was validated in dog trials using nilotinib, a leukemia (搜索) drug, demonstrating the potential to improve effectiveness of approximately 40% of approved oral drugs that currently have compromised efficacy.
The company is now advancing to human trials with healthy volunteers, with the goal of salvaging previously failed drugs and enabling new therapies that were abandoned due to poor bioavailability.
Enzian Pharmaceutics (搜索) has demonstrated that its novel expandable fibrous dosage form can significantly enhance the bioavailability of sparingly water-soluble drugs, potentially addressing a major limitation affecting 40% of approved oral medications. The technology showed a three-fold improvement in bioavailability compared to conventional drug particle-filled capsules in preclinical trials.
Revolutionary Gastroretentive Technology
The new dosage form comprises orderly arranged, drug-bearing fibers that expand upon water absorption after ingestion, forming a gel-like substance that remains in the stomach for prolonged periods. This gastroretentive mechanism enables steady drug release during extended gastric residence, addressing the fundamental challenge of poor bioavailability in sparingly-soluble compounds.
According to Dr. Aron Blaesi, Enzian's founder and CEO, the current limitation stems from the inherently low dissolution and absorption rates of sparingly water-soluble drugs, combined with the short gastric residence time of conventional capsules and tablets. "The drug solubility is low, the drug dissolution rate in the gastrointestinal fluid and the drug absorption rate by the blood are inherently low, too," Blaesi explained.
Preclinical Validation with Nilotinib
The concept was validated through trials on dogs using nilotinib, a sparingly-soluble leukemia (搜索) drug. The Enzian dosage form demonstrated remarkable performance, residing in the stomach for approximately six hours and ensuring three times greater bioavailability than the present drug particle-filled capsule. These results were published in the Royal Society of Chemistry Journal RSC Pharmaceutics.
The extended gastric residence time of six hours represents a significant advancement over conventional dosage forms, which typically have much shorter gastric residence times, limiting drug absorption opportunities.
Broad Therapeutic Implications
The technology addresses a widespread pharmaceutical challenge, with approximately 40% of approved oral-delivery drugs currently experiencing compromised efficacy due to low bioavailability. Blaesi envisions applications beyond improving existing medications: "I am particularly thinking about salvaging drugs that have never made it to market because of poor bioavailability. By increasing the quantity of drug delivered, we might make many of them viable for oral therapy."
This approach could potentially rescue previously abandoned drug candidates and enable new therapies that were deemed unviable due to delivery limitations. "This might enable bringing new drugs and new therapies to market that have so far been neglected, but with the right delivery technology could be far superior to the state of the art," Blaesi added.
Clinical Development Progress
Enzian is currently advancing the fibrous dosage form technology to human testing, validating the approach in a small number of healthy human volunteers. This represents a critical step toward clinical application of the technology.
The company, which emerged from doctoral research at the Massachusetts Institute of Technology (MIT), was founded by Dr. Blaesi with counsel from Dr. Nannaji Saka, also an MIT alumnus. Enzian focuses on developing new oral solid dosage forms for improving drug therapy effectiveness while reducing side effects.